Bile Duct Malignancies

J 2010

Bile Duct Malignancies

TUČEK, Štěpán, Jiří TOMÁŠEK, Jana HALÁMKOVÁ, Igor KISS, Tomáš ANDRAŠINA et. al.

Basic information

Original name

Bile Duct Malignancies

Name in Czech

Malignity žlučových cest.

Authors

TUČEK, Štěpán (203 Czech Republic, guarantor, belonging to the institution), Jiří TOMÁŠEK (203 Czech Republic, belonging to the institution), Jana HALÁMKOVÁ (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution), Beáta HEMMELOVÁ (203 Czech Republic, belonging to the institution), Dagmar ADÁMKOVÁ KRÁKOROVÁ (203 Czech Republic, belonging to the institution) and Rostislav VYZULA (203 Czech Republic, belonging to the institution)

Edition

Klinicka onkologie, 2010, 0862-495X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/10:00046969

Organization unit

Faculty of Medicine

Keywords (in Czech)

nádory žlučových cest, cholangiokarcinom, nádory žlučníku, paliativní terapie

Keywords in English

bile duct neoplasms – cholangiocarcinoma – gallbladder cancer – palliative treatment

Změněno: 11/1/2012 20:35, MUDr. Tomáš Andrašina, Ph.D.

Abstract

V originále

Bile duct malignancies include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), gall bladder carcinoma (GC) and carcinoma of Vater’s ampulla (ampulloma). Bile duct neoplasms are rare tumours with overall poor prognosis. The overall incidence aff ects up to 12.5 per 100,000 persons in the Czech Republic. The mortality rate has risen recently to 9.5 per 100,000 persons. The incidence and mortality have been remarkably stable over the past 3 decades. The survival rate of patients with these tumours is poor, usually not exceeding 12 months. The diagnostic process is complex, uneasy and usually late. Most cases are diagnosed when unresectable, and palliative treatment is the main approach of medical care for these tumours. The treatment remains very challenging. New approaches have not brought much improvement in this fi eld. Standards of palliative care are lacking and quality of life assessments are surprisingly not common. From the scarce data it seems, however, that multimodal individually tailored treatment can prolong patients’ survival and improve the health-related quality of life. The care in specialized centres off ers methods of surgery, interventional radiology, clinical oncology and high quality supportive care. These methods are discussed in the article in greater detail. Improvements in this fi eld can be sought in new diagnostic methods and new procedures in surgery and interventional radiology. Understanding the tumour bio logy on the molecular level could shift the strategy to a more successful one, resulting in more cured patients. Further improvements in palliative care can be sought by defi ning new targets and new drug development. The lack of patients with bile duct neoplasms has been the limiting factor for any improvements. A new design of larger randomized international multicentric clinical trials with prompt data sharing could help to overcome this major problem. Defi ning standards of palliative care is a necessity. Addressing health-related quality of life could help to assess the real benefi t of palliative treatment.

Links

MZ0MOU2005, plan (intention)

Name: Funkční diagnostika zhoubných nádorů

NT11128, research and development project

Name: Endoluminální radiofrekvenční ablace tumorů postihujících žlučové cesty

Citovat

TUČEK, Štěpán, Jiří TOMÁŠEK, Jana HALÁMKOVÁ, Igor KISS, Tomáš ANDRAŠINA, Beáta HEMMELOVÁ, Dagmar ADÁMKOVÁ KRÁKOROVÁ and Rostislav VYZULA. Bile Duct Malignancies. Klinicka onkologie. 2010, roč. 23, č. 4, p. 231-241. ISSN 0862-495X.

@article{921428,
   author = {Tuček, Štěpán and Tomášek, Jiří and Halámková, Jana and Kiss, Igor and Andrašina, Tomáš and Hemmelová, Beáta and Adámková Krákorová, Dagmar and Vyzula, Rostislav},
   article_number = {č. 4},
   keywords = {bile duct neoplasms – cholangiocarcinoma – gallbladder cancer – palliative treatment},
   language = {eng},
   issn = {0862-495X},
   journal = {Klinicka onkologie},
   title = {Bile Duct Malignancies},
   volume = {roč. 23},
   year = {2010}
}

TY  - JOUR
ID  - 921428
AU  - Tuček, Štěpán - Tomášek, Jiří - Halámková, Jana - Kiss, Igor - Andrašina, Tomáš - Hemmelová, Beáta - Adámková Krákorová, Dagmar - Vyzula, Rostislav
PY  - 2010
TI  - Bile Duct Malignancies
JF  - Klinicka onkologie
VL  - roč. 23
IS  - č. 4
SP  - 231-241
EP  - 231-241
SN  - 0862495X
KW  - bile duct neoplasms – cholangiocarcinoma – gallbladder cancer – palliative treatment
N2  - Bile duct malignancies include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), gall bladder carcinoma (GC) and carcinoma of Vater’s ampulla (ampulloma). Bile duct neoplasms are rare tumours with overall poor prognosis. The overall incidence aff ects up to 12.5 per 100,000 persons in the Czech Republic. The mortality rate has risen recently to 9.5 per 100,000 persons. The incidence and mortality have been remarkably stable over the past 3 decades. The survival rate of patients with these tumours is poor, usually not exceeding 12 months. The diagnostic process is complex, uneasy and usually late. Most cases are diagnosed when unresectable, and palliative treatment is the main approach of medical care for these tumours. The treatment remains very challenging. New approaches have not brought much improvement in this fi eld. Standards of palliative care are lacking and quality of life assessments are surprisingly not common. From the scarce data it seems, however, that multimodal individually tailored treatment can prolong patients’ survival and improve the health-related quality of life. The care in specialized centres off ers methods of surgery, interventional radiology, clinical oncology and high quality supportive care. These methods are discussed in the article in greater detail. Improvements in this fi eld can be sought in new diagnostic methods and new procedures in surgery and interventional radiology. Understanding the tumour bio logy on the molecular level could shift the strategy to a more successful one, resulting in more cured patients. Further improvements in palliative care can be sought by defi ning new targets and new drug development. The lack of patients with bile duct neoplasms has been the limiting factor for any improvements. A new design of larger randomized international multicentric clinical trials with prompt data sharing could help to overcome this major problem. Defi ning standards of palliative care is a necessity. Addressing health-related quality of life could help to assess the real benefi t of palliative treatment.
ER  -

TUČEK, Štěpán, Jiří TOMÁŠEK, Jana HALÁMKOVÁ, Igor KISS, Tomáš ANDRAŠINA, Beáta HEMMELOVÁ, Dagmar ADÁMKOVÁ KRÁKOROVÁ and Rostislav VYZULA. Bile Duct Malignancies. \textit{Klinicka onkologie}. 2010, roč. 23, č. 4, p.~231-241. ISSN~0862-495X.

Detailed Information on Publication Record